Xiangyu Zhong

Xiangyu Zhong


Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 April 2019 in Aging
Verified
Journal Article
Closed access
YXYi Xu
Yi Xu
YYYue Yao
Yue Yao
YLYueping Liu
Yueping Liu
ZWZhidong Wang
Zhidong Wang
ZHZhanliang Hu
Zhanliang Hu
YCYunfu Cui
Yunfu Cui
Cholangiocarcinoma (CCA) is a highly malignant carcinoma with high mortality rate worldwide. Emerging evidence indicates that aberrantly expressed circular RNAs (circRNAs) functions crucial roles in tumor progression. In this work, we focused on a novel circRNA, circ_0005230, in carcinogenesis and development of CCA. Circ_0005230 levels in CCA specimens and cells were measured by qRT-PCR. The clinical implication of circ_0005230 was analyzed by fisher's exact test. Gain/loss of-function assays were conducted to reveal the effects of circ_0005230 on the cell proliferation, apoptosis, migration and invasion of CCA cells. Xenograft and lung metastatic models were constructed to confirm the in vitro data. Dual luciferase reporter and rescue assays were carried out to illuminate the mechanism behind the regulatory actions. As data showed, circ_0005230 was elevated in tumors and CCA cells. Its expression in tumor samples was related to clinical severity. Functionally, circ_0005230 significantly facilitated cell growth, clone-forming ability and metastatic properties and inhibit cell apoptosis in CCA cells. The in vivo study further validated the in vitro results. However, knockdown of circ_0005230 did not affect normal biliary epithelial (HIBEC) cell growth and apoptosis. For the mechanism investigation, circ_0005230 could directly sponge miR-1238 and miR-1299 to exert its oncogenic functions. Overall, this work showed that circ_0005230 might act as an effective therapeutic target for CCA.

15 August 2018 in Scientific Reports
Verified
Journal Article
Open access
PDF file
WQWei Qin
Wei Qin
PKPengcheng Kang
Pengcheng Kang
YXYi Xu
Yi Xu
KLKaiming Leng
Kaiming Leng
ZLZhenglong Li
Zhenglong Li
XZXiangyu Zhong
Xiangyu Zhong
Cholangiocarcinoma (CCA) arising from the neoplastic transformation of cholangiocytes with increasing incidence in the worldwide. Unfortunately, a large amount of CCA patients lost their chance for surgery because it is hard to diagnose in the early stages. Long non-coding RNAs (lncRNAs) is closely associated with development and progression of various malignant tumors. Hox transcript antisense intergenic (HOTAIR), a negative prognostic factor for patients with gastric, liver and pancreatic carcinoma. Its transcription levels and functional roles in CCA is still unknown. Therefore, we aimed to explore the effect of HOTAIR in CCA including cell proliferation, apoptosis, migration, invasion and epithelial-to-mesenchymal transition (EMT). The results showed that HOTAIR was highly expressed both in CCA tissue samples and cell lines compared with corresponding normal bile duct tissues and Human intrahepatic biliary epithelial cells (HIBEC). Its overexpression was closely correlated with Tumor size, TNM stage and postoperative recurrence in CCA patients. Moreover, up-regulation of HOTAIR has correlation with prognosis in CCA patients. Knockdown of HOTAIR by siRNAs significantly decreased the migration and invasion but increased apoptosis of CCA cells in vitro. Overall, our study revealed that HOTAIR may play as a new potential therapeutic target and forecast poor prognosis for this fatal disease.

1 August 2023 in Nature Communications
Verified
Journal Article
Open access
PDF file
XHXiang Huang
Xiang Huang
XLXin Liu
Xin Liu
XLXingda Li
Xingda Li
YZYang Zhang
Yang Zhang
JGJianjun Gao
Jianjun Gao
ZPZhenwei Pan
Zhenwei Pan
Nonalcoholic fatty liver disease (NAFLD) is the most common liver disorder with high morbidity and mortality. The current study aims to explore the role of Cullin-associated and neddylation-dissociated protein 1 (CAND1) in the development of NAFLD and the underlying mechanisms. CAND1 is reduced in the liver of NAFLD male patients and high fat diet (HFD)-fed male mice. CAND1 alleviates palmitate (PA) induced lipid accumulation in vitro. Hepatocyte-specific knockout of CAND1 exacerbates HFD-induced liver injury in HFD-fed male mice, while hepatocyte-specific knockin of CAND1 ameliorates these pathological changes. Mechanistically, deficiency of CAND1 enhances the assembly of Cullin1, F-box only protein 42 (FBXO42) and acetyl-CoA acyltransferase 2 (ACAA2) complexes, and thus promotes the ubiquitinated degradation of ACAA2. ACAA2 overexpression abolishes the exacerbated effects of CAND1 deficiency on NAFLD. Additionally, androgen receptor binds to the −187 to −2000 promoter region of CAND1. Collectively, CAND1 mitigates NAFLD by inhibiting Cullin1/FBXO42 mediated ACAA2 degradation.

6 March 2021 in Journal of Cellular and Molecular Medicine
Verified
Journal Article
Open access
PDF file
YXYi Xu
Yi Xu
PGPing Gao
Ping Gao
ZWZhidong Wang
Zhidong Wang
ZSZhilei Su
Zhilei Su
GLGuanqun Liao
Guanqun Liao
XZXiangyu Zhong
Xiangyu Zhong
Dysregulation of circular RNAs (circRNAs) executes important regulatory roles in carcinogenesis. Nonetheless, few studies focused on the mechanisms of circRNAs in cholangiocarcinoma (CCA). qRT‐PCR was applied to verify the dysregulated circRNAs in CCA. Fisher's exact test, Kaplan‐Meier analysis and Cox regression model were utilized to investigate the clinical implications of circ‐LAMP1 in the patients with CCA. The viability, apoptosis, migration and invasion of CCA cells were detected after silencing/overexpression of circ‐LAMP1. Xenograft and lung metastasis assays were performed to verify the in vitro results. The regulatory networks of circ‐LAMP1 were unveiled by bioinformatic analysis, RNA immunoprecipitation (RIP), RNA pulldown and luciferase reporter assays. Up‐regulation of circ‐LAMP1 was found in CCA tissue samples and cell lines. Enhanced level of circ‐LAMP1 was linked to clinical severity, high post‐operative recurrence and poor prognosis for the patients with CCA. Gain/loss‐of‐function assays confirmed the oncogenic role of circ‐LAMP1 in mediating cell growth, apoptosis, migration and invasion. Nevertheless, the level of circ‐LAMP1 had no effect on normal biliary epithelium proliferation and apoptosis. Animal study further verified the in vitro data. Mechanistically, circ‐LAMP1 directly sponged miR‐556‐5p and miR‐567, thereby releasing their suppression on YY1 at post‐transcriptional level. Rescue assay indicated that the oncogenic role of circ‐LAMP1 is partially dependent on its modulation of YY1 in CCA. In summary, this study suggested that circ‐LAMP1 might be used as a promising biomarker/therapeutic target for CCA.

20 April 2023 in Frontiers in Medicine
Verified
Journal Article
Open access
QDQingfu Dong
Qingfu Dong
HBHaolin Bao
Haolin Bao
JWJiangang Wang
Jiangang Wang
WSWujiang Shi
Wujiang Shi
XZXinlei Zou
Xinlei Zou
XZXiangyu Zhong
Xiangyu Zhong
In recent years, the prevalence of metabolic-associated fatty liver disease (MAFLD) has reached pandemic proportions as a leading cause of liver fibrosis worldwide. However, the stage of liver fibrosis is associated with an increased risk of severe liver-related and cardiovascular events and is the strongest predictor of mortality in MAFLD patients. More and more people believe that MAFLD is a multifactorial disease with multiple pathways are involved in promoting the progression of liver fibrosis. Numerous drug targets and drugs have been explored for various anti-fibrosis pathways. The treatment of single medicines is brutal to obtain satisfactory results, so the strategies of multi-drug combination therapies have attracted increasing attention. In this review, we discuss the mechanism of MAFLD-related liver fibrosis and its regression, summarize the current intervention and treatment methods for this disease, and focus on the analysis of drug combination strategies for MAFLD and its subsequent liver fibrosis in recent years to explore safer and more effective multi-drug combination therapy strategies.

12 April 2024 in Frontiers in Pharmacology
Verified
Journal Article
Open access
PDF file
JGJianjun Gao
Jianjun Gao
WSWujiang Shi
Wujiang Shi
JWJiangang Wang
Jiangang Wang
CGCanghai Guan
Canghai Guan
QDQingfu Dong
Qingfu Dong
YCYunfu Cui
Yunfu Cui
Epigenetic changes are heritable changes in gene expression without changes in the nucleotide sequence of genes. Epigenetic changes play an important role in the development of cancer and in the process of malignancy metastasis. Previous studies have shown that abnormal epigenetic changes can be used as biomarkers for disease status and disease prediction. The reversibility and controllability of epigenetic modification changes also provide new strategies for early disease prevention and treatment. In addition, corresponding drug development has also reached the clinical stage. In this paper, we will discuss the recent progress and application status of tumor epigenetic biomarkers from three perspectives: DNA methylation, non-coding RNA, and histone modification, in order to provide new opportunities for additional tumor research and applications.